JP2023512487A - 癌を治療するための投与養生法および方法 - Google Patents

癌を治療するための投与養生法および方法 Download PDF

Info

Publication number
JP2023512487A
JP2023512487A JP2022543648A JP2022543648A JP2023512487A JP 2023512487 A JP2023512487 A JP 2023512487A JP 2022543648 A JP2022543648 A JP 2022543648A JP 2022543648 A JP2022543648 A JP 2022543648A JP 2023512487 A JP2023512487 A JP 2023512487A
Authority
JP
Japan
Prior art keywords
2dehspm
cancer
treatment
patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022543648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512487A5 (https=
Inventor
ガニョン，スザンヌ
ニーナン，トマス，エックス．
カレン，マイケル，ティー．
ウォーカー，マイケル
Original Assignee
パンベラ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パンベラ セラピューティクス インコーポレイテッド filed Critical パンベラ セラピューティクス インコーポレイテッド
Publication of JP2023512487A publication Critical patent/JP2023512487A/ja
Publication of JP2023512487A5 publication Critical patent/JP2023512487A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022543648A 2020-01-20 2021-01-20 癌を治療するための投与養生法および方法 Pending JP2023512487A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062963492P 2020-01-20 2020-01-20
US62/963,492 2020-01-20
PCT/US2021/014112 WO2021150559A1 (en) 2020-01-20 2021-01-20 Dosing regimens and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2023512487A true JP2023512487A (ja) 2023-03-27
JP2023512487A5 JP2023512487A5 (https=) 2024-01-24

Family

ID=76992702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022543648A Pending JP2023512487A (ja) 2020-01-20 2021-01-20 癌を治療するための投与養生法および方法

Country Status (6)

Country Link
US (1) US20230064990A1 (https=)
EP (1) EP4093386A4 (https=)
JP (1) JP2023512487A (https=)
AU (1) AU2021210867A1 (https=)
CA (1) CA3164914A1 (https=)
WO (1) WO2021150559A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501282A (ja) * 2022-12-20 2026-01-14 ジェネンテック， インコーポレイテッド Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いて膵臓がんを処置する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160022A (en) * 1999-07-19 2000-12-12 University Of Florida Chemical resection of pancreas
US20130137772A1 (en) * 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
WO2017062704A1 (en) * 2015-10-08 2017-04-13 Sun Biopharma, Inc. Compositions and methods for treating pancreatitis
US10195188B2 (en) * 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
EP4257581A1 (en) * 2018-01-30 2023-10-11 Panbela Therapeutics, Inc. Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 2014年, Vol.74, No.19, Supplement, JPN6025000461, pages 3128, ISSN: 0005653476 *
JOURNAL CLINIAL ONCOLOGY, vol. Vol.36, No.15, Supplement, JPN6025000458, 2018, pages 16231, ISSN: 0005501068 *
PANCREAS, vol. 2015年, Vol.44, No.8, JPN6025000459, pages 1360 - 1361, ISSN: 0005501067 *
PANCREAS, vol. 44, no. 8, JPN6025000460, 2015, pages 1413 - 1414, ISSN: 0005501066 *

Also Published As

Publication number Publication date
EP4093386A1 (en) 2022-11-30
EP4093386A4 (en) 2024-01-10
AU2021210867A1 (en) 2022-08-18
WO2021150559A1 (en) 2021-07-29
US20230064990A1 (en) 2023-03-02
CA3164914A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US11980652B2 (en) Compositions and methods for subcutaneous administration of cancer immunotherapy
EP3126007B1 (en) Methods for enhancing the efficacy of a tumor-directed immune response
KR20240132482A (ko) 항암 백시니아 바이러스와 관문 저해제 병용 요법
US20250032582A1 (en) Compositions and methods for cancer immunotherapy
US20230064990A1 (en) Dosing regimens and methods for treating cancer
US20230181633A1 (en) Methods of treating cancer using a combination of tumor membrane vesicles and metformin
WO2025207491A1 (en) Compositions and methods for cancer immunotherapy
CN115916241A (zh) 与血管生成抑制剂组合的免疫刺激剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250730